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OUTCOME OF CHINESE CHILDREN WITH UNRELATED DONOR HEMATO-
POIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERI-
ENCE
Chen, J., Luo, C., Jiang, H., Luo, C., Tang, J., Gu, L. Shanghai Jiao
Tong University School of Medicine, Shanghai Children’s Medical Center,
Shanghai, China
Background: To evaluate the outcome and prognostic factors in
Chinese children undergoing matched unrelated donor hematopoi-
etic stem cell transplantation (UDT).
Methods: Retrospective analysis of clinical data of 53 consecutive
children received URT between November 2002 to December
2007 in our center was performed. Conditioning regimen for Acute
lymphoblastic leukemia (ALL) was total body irradiation based,
aplastic anemia (AA) was fludarabine based. The other patients re-
ceived busulphan based myeloablative regimen.
Results:Themedian age was 8.4 years (range, 1.521) with the me-
dian follow up 36 months (range, 1880). The probability of 3-year
overall survival (OS) was 71.5%.Treatment relatedmortality (TRM)
was 19.0%. 9.4% died after post-transplant leukemia relapse. Inci-
dence of Grade I-II and III-IV acute and chronic GVHD was
63%, 29% and 46%. There was significant difference of OS for pa-
tients older or younger than 10 years(50.0% vs 84.8%, p5 0.003)and
patients with different underlying diseases (ALL, AML, CML and
non-malignant disease: 36.4%, 80.0%, 61.5% and 100%,
p5 0.001). There was also significant difference of OS for patients
with low-risk, high-risk leukemia (83.3% vs 42.9%, p5 0.013) and
patient received HLA 0-1 locus 2-3 loci high resolution mismatched
transplant (83.3% vs 53.3%, p5 0.034). But there was no significant
difference of OS among the patient received peripheral stem cell,
bone marrow or cord blood transplant (70.3%,87.5%,62.5%,
p5 0.542) and patients with 0-II and III-IV acute GVHD (77.8%
vs 60.0%, p5 0.140).
Conclusions: The important prognostic factors for OS after UDT
were the degree of HLAmatch, the age of patient and the type of un-
derlying disease. Patients less than 10 year with non-malignant dis-
ease receiving 0-1 locus high resolution mismatched UDT had the
best outcome. Myeloid, low-risk leukemia was superior to other leu-
kemia.373
IV BUSULFAN-BASED REDUCED INTENSITY REGIMEN (RIC) BEFORE AL-
LOGENEIC STEM CELL TRANSPLANTATION IS WELL TOLERATE AND EF-
FECTIVE IN PATIENTS WITH HEMATOLOGICAL DISEASES
Castagna, L.1, Fu¨rst, S.1, El-Cheikh, J.1, Faucher, C.1, Vey, N.1,
Bouabdallah, R.1, Stoppa, A.-M.1, Mohty, M.2, Chabannon, C.1,
Esterni, B.3, Blaise, D.1 1 Institut Paoli Calmettes, Marseille, France;
2 CHU Hotel Dieu, Nantes, France; 3 Institut Paoli Calmettes, Marseille,
France
Background: Busulfan-based RIC has been widely used in Alloge-
neic setting, showing good safety profile and efficacy. The intrave-
nous formulation, Busilvex, is considered a step forward as
compared to oral form because of reproducible biodisponibility
and pharmacokinetic. In this study, we evaluated the toxic profile
and clinical efficacy of a busilvex-based RIC.
Patients and methods: Since 2005, 78 patients received a uniform
RIC consisting of busilvex 3.2 mg/kg/day for 2 days, Fludarabine
40 mg/m2/days for 5 days, and thymoglobulin 2.5 mg/kg/day for 2
days. Cyclosporine was used as post-graft immunesuppression.
The median age was 58 years (24-70), and 41% of patients suffered
from acute myeloid leukemia. 81% were in complete or partial re-
mission before RIC. Donor was a HLA identical sibling for 64%
of patients. 43% of patients received previous high dose chemother-
apy.
Results: The median follow-up was 16 (2-51). No patients devel-
oped venocclusive disease (VOD). The cumulative incidence (CI)
for grade II-IV acute graft versus host disease (GVHD) was
31%, and for extensive chronic GVHD was 25%. Overall 9 pts
died from TRM for a 2 year CI of 16% (8-28). In addition, 18
pts relapsed or progressed for a 2 year CI of relapse progression
of 30% (17-48). Overall the 2-y overall survival (OS) and diseasefree survival (DFS) probabilities were respectively 71% (56-82)
and 58% (42-72).
Conclusions: This retrospective study shows that busilvex-based
RIC is well tolerate with low TRM incidence in a high-risk cohort
of patients. Particularly, the extensive chronic GVHD incidence
was low probably due to thymoglobulin use for HLA identical do-
nors. VOD was absent even if reversible hepatic toxicity was fre-
quently observed. These promising safety results invited us to
assess the impact of higher dose of IV Busulfan in an ongoing trial
in order to improve disease control.374
OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC
LEUKEMIA
Rashed, A., Corringham, S., Castro, J.E., Kipps, T.J., Ball, E.D. Univer-
sity of California, San Diego, La Jolla, CA
Allogeneic hematopoietic stem cell transplantation (HSCT) is
a treatment increasingly used for patients with chronic lympho-
cytic leukemia (CLL). There is no curative treatment for patients
with advanced CLL. However, prolonged disease-free survival
has been shown in patients after allogeneic HSCT. The aim of
the study was to analyze the outcome of patients with CLL
treated at our institution with either non-myeloablative (n5 12)
or myeloablative (n5 1) conditioned allogeneic HSCT. Thirteen
patients (5 males [5 Caucasian], 8 females [7 Caucasian, 1 His-
panic]) diagnosed with CLL who underwent allogeneic HSCT
from related (n5 7) and unrelated (n5 6) donors between No-
vember 1998 and July 2009 were included in this analysis. The
median age was 55 (age range 47-75), median interval between
diagnosis and HSCT was 1,556 days, and the median number
of regimens prior to transplant was 5 (range 2-7). Of the 13 pa-
tients, 5 were fludarabine-refractory and 1 was not evaluable
(NE). 12 patients received a fludarabine-based non-myeloablative
conditioning regimen, while 1 patient received an ablative cyclo-
phosphamide/total body irradiation regimen. Prior to transplant,
4 patients had progressive disease (PD), 6 patients were in partial
remission (PR), and 3 patients were in complete remission (CR).
Disease status was re-assessed 30 days post allogeneic HSCT. At
this time post-transplant, 6 patients were in CR, 4 were in PR, 1
was in stable disease (SD), 1 had PD, and 1 was NE. Thus, at
day 30, 11 of the 13 patients improved or were stable. Of the
remaining 2 patients, 1 continued to progress and 1 died of
multi-organ failure 16 days post transplant. At the time of this
report, median times to progression and overall survival were
467 and 1,843 days respectively. The Kaplan-Meier probabilities
of progression-free survival (PFS) and overall survival (OS) at
three-years were 43% and 84%, and the five-year PFS and OS
were 43% and 43%, respectively. Differences in the outcomes
were not apparent between matched related and unrelated do-
nors. Our results indicate that long-term survival after allogeneic
HSCT can be achieved in heavily pre-treated high-risk CLL pa-
tients. This treatment should be offered to patients with matched
donors and good performance status that have demonstrated
resistance to available chemotherapy and biological therapy
regimens.375
OUTPATIENT HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PE-
DIATRIC PATIENTS. PRELIMINARY RESULTS IN A SINGLE INSTITUTION
IN MEXICO
Gonzalez, O., Rodrıguez, L.N., Mancıas, C., Tarın, L., Salazar, R.,
Jaime, J.C., Cantu, O.G., Gutierrez, H., Gomez, D. University Hospital,
UANL, Monterrey, Nuevo Leon, Mexico
Introduction: Hematopoietic cell transplantation (HCT) is a well-
established treatment for several nonmalignant and malignant
diseases in children. However, only 25% of children have an HLA
identical sibling, and a suitably matched unrelated donor does not
Patients Characteristics
Case Diagnosis CD3/kg CD34/kg Chimeras Acute GVHD Status/time post-transplant
1 ALL in 3 CR 2x106 18x106 86% No Alive-Remission/ 9 months
2 ALL in 3 CR 5x105 10x106 100% No Alive-Remission/ 2 months
3 ALL in 2 CR 2x105 12x106 13% No Alive-Remission/ 2 months
4 AML in 2 CR 6x105 6.9x106 100% Skin grade III Relapse at 3 months/
5 Sickle cell disease 14x105 7.8x106 Pending No Alive/1 month
6 Sickle cell disease/ Thalasemia 13x105 8.6x106 86% No Alive/ 2 month
7 ALL high risk in 1 CR 3.4x105 12x106 100% Skin grade I Alive-Remission/ 4 months
8 ALL in 2 CR 8.6x105 6.7x106 90% Skin and intestine II Alive-Remission/ 4 months.
9 AML in 2 CR 2.1x106 11.2x106 — — —
10 ALL in 2 CR 1.2 x106 15 x106 — — —
S296 Poster Session IIexist or will not be found within an acceptable time frame for a sub-
stantial portion of the remaining patients. Haploidentical HCT is
a viable alternative since almost every patient has at least a haplo-
type-sharing parent, child, or sibling available to donate stem cells,
but it has been limited by high risk of severe graft-versus-host disease
(GVHD), graft rejection, life-threatening infections, and relapse—
all of which are partially caused by intensive immunosuppressive
therapy and T-cell depletion.
Patients and methods: Between January and October 2009 all
pediatric patients (ten patients) in our center who needed trans-
plant without a suitable donor were included in our haploident-
ical transplant program. The median age of the patients was 7
years (range between 2 and 11 years), five boys and five girls.
The HLA compatibility was 7/10 in one patient, 8/10 in one pa-
tient and 5/10 in 8 patients. In all the cases the mother was the
donor.
The patients received the following conditioning regimen in out-
patient basis, thymoglobulin (from day -10 to day -7), cyclophospha-
mide (from day -6 to day -3), fludarabine (from day -6 to day -3), (on
day -2), cyclosporine (begin day -1), stem cells infusion (day 0).
GVHD was with prednisone, cyclosporine and low doses of metho-
trexate, and, depending on the T cell dose, mycophenolate was used.
More characteristics are show in table 1.
Results: Eight of 10 patients could be evaluated. Engraftment was
achieved in all patients. However, two of them rejected afterwards.
One patient received a second cells infusion. Three patients pre-
sented mild GVHD. A bone marrow relapse happened in a patient
with acute myelogenous leukemia, and a patient die for transplant
lymphoproliferative disorder without neoplastic activity and with
a 100% chimerism.
Conclusions: We have demonstrated in a small group of patients
that the use of stem cells from haploidentical parental donors should
be strongly considered in children who need transplantation but lack
of a match-related donor. Long-term follow-up and a large number
of patients for a better analysis are needed.376
LATE ONSET INTESTINAL PERFORATION IN THE SETTING OF POST-
TRANSPLANT MIRCOANGIOPATHY: A REPORT OF TWO CASES
Aljitawi, O.S.1, Rodriguez, L.1, Divine, C.1, Ganguly, S.1,
Abhyankar, S.1, Madan, R.2, McGuirk, J.L.1 1 University of Kansas Med-
ical Center, Kansas City, KS; 2 University of Kansas Medical Center, Kan-
sas City, KS
Background: Intestinal perforation in the setting of post-transplant
microangiopathy (TMA) is a very rare event andmight be considered
a terminal event of intestinal microangiopathy (i-TMA), a rather
rarely recognized post-transplant complication, as it overlaps with
the more common intestinal graft-versus-host-disease (GVHD).
Cases of i-TMA described in literature occurred within with first
100-days post-transplant or shortly thereafter. The aim of this study
is to describe two cases of late onset intestinal perforation thatoccurred in the setting of systemic microangiopathy more than
a year post allogeneic transplant.
Results:One patient presented 380 days post matched unrelated
allogeneic transplantation with acute respiratory distress second-
ary to diffuse alveolar hemorrhage. Five days later she developed
constipation and abdominal distension. An ultrasound of the ab-
domen revealed portal venous gas and multiple loops of dilated
fluid filled bowel concerning for bowel ischemia. She underwent
exploratory laparatomy and subsequent subtotal colectomy. Path-
ologic examination confirmed ischemic necrosis. She fulfilled the
criteria for TMA diagnosis and was started on plasmapheresis
and rituximab. Tacrolimus was discontinued prior to her admis-
sion. Despite these measures, the patient passed away from pro-
gressive TMA 17 days after surgery. The second patient
presented two years post matched unrelated donor transplant
with abdominal pain in the setting of sepsis. Admission CT
scan revealed perisplenic gas and fluid collection concerning for
possible abscess. An exploratory laparatomy revealed diffuse is-
chemic large bowel requiring a hemicolectomy. Pathologic exam-
ination was consistent with chronic ischemic changes with
intestinal mucosal fibrosis and focal ulceration. He also fulfilled
the criteria for diagnosis of TMA and calcineurin inhibitor was
discontinued. Ultimately, he died of sepsis and unresponsive
TMA. Both patients, prior to their presentation, were treated
for chronic GVHD of the liver and lower gastrointestinal tract
with steroids in addition to tacrolimus. The final pathologic
exam did not show evidence of GVHD in the first case, but
did show crypt apoptosis and crypt abscess in the second case,
raising the possibility of associated GVHD.
Conclusion: Intestinal perforation in the setting of TMA can oc-
cur as a late post-transplant complication, and is associated with
poor response to treatment secondary to refractory mircoangio-
pathy.377
RESPONSES TO A QUESTIONNAIRE FOR PATIENTS ABOUT BONE MAR-
ROW TRANSPLANTATION
Van Hoef, M.E.H.M. Transplant Creations, Amsterdam, Noord Holland,
Netherlands
Introduction: In the context of our focus on treatment by hemato-
poietic cell transplantation as part of therapy a questionnaire was de-
veloped to offer patients visiting the website or link at a public sites to
respond.
Method:A survey was prepared containing 20 questions, 6 related to
general responders characteristics, 10 to autologous and allogeneic
transplantation, and 4 to donation of bone marrow, interest in edu-
cation about transplantation and donation for clinical research or
treatment by transpant. All yes/no questions also had the option
not applicable or uncertain.
The results were analysed as % of all responders and % of re-
sponders to a question. Herein we present as % of all respondsers.
